0919 GMT - Sanofi's incoming CEO Belen Garijo needs to be clear on her strategic priorities, as the French drugmaker still needs to rebuild its drug pipeline, Citi analysts say in a research note. The company aims to defend the exclusivity of its blockbuster anti-inflammatory drug Dupixent--jointly developed with Regeneron--beyond the U.S. compound patent expiration in March 2031, Citi says. It also aims to extend dosing and leverage its alliance with Regeneron to bring new drugs to market, the analysts say. Sanofi has flagged financial firepower of between 15 billion and 25 billion euros for acquisitions and dealmaking, according to Citi. While the plan looks sensible, Sanofi needs to show it is rebuilding its pipeline for shares to recover, the analysts add. Shares fall 0.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 27, 2026 05:19 ET (09:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.